Bioventus INC Form 4 insider transactions

Director Susan M. Stalnecker reports the vesting and subsequent disposal of 30,400 Class A Common Stock restricted stock units on June 7, 2024.

Director Guy P. Nohra reports the vesting and conversion of restricted stock units into Class A Common Stock of Bioventus Inc.

Director Guido J. Neels reports the vesting and conversion of restricted stock units into Class A Common Stock on June 7, 2024.

Director William A. Hawkins reports the vesting and conversion of restricted stock units into Class A Common Stock of Bioventus Inc.

Director Ladone Mary Kay reports the vesting and conversion of restricted stock units into Class A Common Stock of Bioventus Inc.

Director Michelle McMurry-Heath reports the vesting and subsequent acquisition of 30,400 shares of Bioventus Inc. Class A Common Stock on June 7, 2024, resulting from the vesting of Restricted Stock Units.

Director Pat Beyer reports the vesting and conversion of restricted stock units into Class A Common Stock on June 7, 2024.

Director John A. Bartholdson reports acquisition of 30,400 Class A Common Stock shares and vesting of 30,400 Restricted Stock Units on June 7, 2024.

Director John A. Bartholdson reports a transaction involving Class A Common Stock and Restricted Stock Units of Bioventus Inc.

Mark Leonard Singleton, SVP & CFO of Bioventus Inc., reported the sale of 4,000 shares of Class A Common Stock on April 11, 2024, at a price of $4.75 per share.

Anthony D'Adamio, SVP & General Counsel of Bioventus Inc., sold 3,054 shares of Class A Common Stock to cover taxes upon the vesting of restricted stock units.

Katrina J. Church, SVP & Chief Compliance Officer of Bioventus Inc., sold 1,325 shares of Class A Common Stock on April 11, 2024, to cover taxes upon the vesting of restricted stock units.

Mark Leonard Singleton, SVP & CFO of Bioventus Inc., reports the vesting of 13,000 restricted stock units and subsequent acquisition of Class A Common Stock on April 10, 2024.

Anthony D'Adamio, SVP & General Counsel of Bioventus Inc., reports the acquisition of 9,925 Class A Common Stock units through the vesting of restricted stock units on April 10, 2024.

Katrina J. Church, SVP & Chief Compliance Officer of Bioventus Inc., reports the vesting of restricted stock units and subsequent acquisition of Class A Common Stock.

Mark Leonard Singleton, SVP & CFO of Bioventus Inc., reports the vesting and sale of Class A Common Stock to cover taxes.

Mark Leonard Singleton, SVP & CFO of Bioventus Inc., reports the acquisition of restricted stock units and stock options.

Anthony D'Adamio, SVP & General Counsel of Bioventus Inc., reports the acquisition of restricted stock units and stock options.

Katrina J. Church, SVP & Chief Compliance Officer of Bioventus Inc., reports the acquisition of stock options and restricted stock units.

Anthony D'Adamio, SVP & General Counsel of Bioventus Inc., reports the sale of 3,125 shares of Class A Common Stock to cover taxes upon the vesting of restricted stock units.

Katrina J. Church, SVP & Chief Compliance Officer of Bioventus Inc., reports the sale of 1,217 shares of Class A Common Stock to cover taxes upon vesting of restricted stock units.

Anthony D'Adamio, SVP & General Counsel of Bioventus Inc., reports the vesting of restricted stock units and subsequent acquisition of Class A Common Stock.

Katrina J. Church, SVP & Chief Compliance Officer of Bioventus Inc., reports the vesting of restricted stock units and subsequent acquisition of Class A Common Stock on March 14, 2024.